Crowdonomics
All companies
Statum Systems logo

Statum Systems

Operating

Statum Systems Inc.

Healthcare · Natick, MA · Founded 2018

Secure Medical Communications

Post-money valuation ⓘ
$62.9M
As of Sep 2022 · from Reg CF Offering (2022) · pre-money + amount raised, not a traded price
Total raised
$348,339
Crowd $228K · Private $120K · 3 rounds since 2020
Latest share price
$1.20
Reg CF · Common Stock · Jun 2022 offering price

Financials

FY2018–FY2023 · from SEC filings · hover any figure for its source
$0
−$23K
2018
$0
−$796K
2019
$0
−$788K
2020
$0
−$876K
2021
$0
−$1.1M
2022
$0
−$1.3M
2023
RevenueNet income — beside revenue when positive, below the line when a loss
Metric
FY2018
FY2019 reviewed*
FY2020 unaudited
FY2021 reviewed
FY2022 reviewed
FY2023
Income statement
Revenue
$0
$0
$0
$0
$0
$0
Cost of goods sold
$0
$0
$0
$0
$0
$0
Net income
-$22,941
-$795,659
-$787,550
-$875,900
-$1,143,831
-$1,330,620
Taxes paid
$0
$0
$0
$0
$0
$0
Balance sheet
Cash
$43,605
$74,984
$74,984
$226,703
$221,896
$75,702
Accounts receivable
$0
$0
$0
$0
$0
$0
Total assets
$43,605
$85,082
$85,082
$252,491
$235,388
$95,578
Short-term debt
$6,346
$130,458
$130,458
$488,958
$663,596
$2,048,639
Long-term debt
$60,000
$765,005
$765,005
$1,301,258
$2,049,712
$1,785,000
Total liabilities
$66,346
$895,463
$895,463
$1,790,216
$2,713,308
$3,833,639
Other
Headcount
—
4
—
4
4
4

Figures as reported by the issuer in the filing shown on hover. Each year’s pill shows the assurance level of its filed statements — audited, reviewed (CPA review, less than an audit), or unaudited, as the filing’s own report or certification states it. A dashed pill marked * is inferred instead: the SEC minimum for an offering that size, which the issuer may have exceeded. No pill means we couldn’t tell. Headcount is the filing’s point-in-time count, not a year-end average. Manually corrected figures are marked “Corrected”.

Valuation over rounds

Pre-money — the valuation set before each round’s money came in
$5.0M
pre-money
$62.9M
pre-money
Reg CF · Common · Sep 2020
Reg CF · Common · Jun 2022

Blue bars are the pre-money valuation the company stated for a priced round.

Share price over rounds

$1.20$0.60$1.00
Sep 2020Jun 2022
Round offering price or verified disclosed saleDisclosed sale, unverified or year-only

Disclosed sales come from the issuer's own filings (prior-offering lines, audited-statement notes) and are amount ÷ securities sold. A down round is a firm point more than 25 % below the previous firm point of the same share class on a comparable basis; the comparison ignores unverified and year-only lines.

Fundraising history

Reg CF · Common Stock · Jun 2022Withdrawnvia StartEngine
Raised $5.7K / $535KInvestors 10Post-money $62.9M
Raised $228.3K / $1.1MInvestors 277Post-money $5.2M
Raised $120KInvestors 4

Team

7 people
Ara Nazarian, Ph.DFounder
Co-Founder and Chief Science Officer

Ara Nazarian has a Ph.D in biomedical engineering and is Associate Professor at Harvard Medical School, where he is Director of the Nazarian Lab. A passionate entrepreneur, he has co-founded numerous other businesses including Ortholevo, Verispellis and OstyMeditech He currently services 20 hours per week in his role with the company.

Fred LizzaFounder
CEO

Fred Lizza is a serial technology company CEO, having led six prior companies ranging in size from pre-revenue startups to $100 million+ in revenue. His experience includes leading a company to its IPO, acquiring businesses to accelerate growth and launching new technologies.

Arman Serebrakian, MD
Co-Founder

Arman Serebrakian is a resident surgeon in plastic and reconstructive surgery at a leading Boston area medical center. Dr. Serebrakian is a daily user of the hospital communications systems in need of improvement. Dr. Serebrakian competed in the 2014 Sochi Olympics in alpine skiing.

Frederick Lizza
CEO and Director
Stephen Okajima
Chief Technology Officer

Stephen Okajima has degrees in biomedical engineering and computer science. He leads Statum Systems’ product development efforts. Mr. Okajima is also a co-founder of Surgibox.

Per Suneby
SVP of Corporate Development

Per Suneby is a Board Observer and Advisor to the Company, and also functions as the Head of Corporate Development for Statum Systems. Mr. Suneby is a noted advisor to early stage technology companies with a record of successful innovation. He has held numerous roles, including CEO. Mr. Suneby has an MBA from Harvard Business School. He currently services 16 hours per week in his role with the company.

Ara Nazarian
Director

Names and titles as disclosed on StartEngine, SEC Form C. Bios and photos come from the platform campaign page and may be out of date.

Reg CF annual-report compliance

Not requiredFiled Form C-TR (terminated reporting)

Filed 3 of 6 annual reports (FY2020–FY2025)

277 investors
holder-count proxy

Reg CF issuers must file a Form C-AR each year until a Rule 202(b) termination trigger is met.

  • Form C-TRSep 18, 20230001665160-23-001763
    EDGAR
  • Form C-ARApr 21, 20230001713695-23-000004
    EDGAR
  • Form C-UOct 7, 20220001665160-22-002681
    EDGAR
  • Form C-WSep 26, 20220001665160-22-002486
    EDGAR
  • Form CJun 17, 20220001665160-22-001824
    EDGAR
  • Form C-ARApr 28, 20220001713695-22-000005
    EDGAR
  • Form C-ARApr 30, 20210001819418-21-000003
    EDGAR
  • Form C-UDec 22, 20200001665160-20-001571
    EDGAR
Source: ManualCIK 0001819418DEShare price $1.20

About this data. Figures are compiled from public sources — SEC EDGAR filings (Form C, C-AR, 1-A, 1-K) and funding-platform pages — and may be delayed, incomplete, or restated by the issuer. Financial statements are as reported by the issuer; each year is labeled with its assurance level (audited / reviewed / unaudited). A valuation cap is the conversion ceiling of a SAFE or convertible note, not an agreed company valuation; post-money figures are computed as pre-money plus amount raised and are not a traded price. Crowdonomics is not a broker-dealer, funding portal, or investment adviser; nothing here is investment advice or an offer to sell securities. Verify all figures against the linked EDGAR filings.